Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account
We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading
Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

Previously untreated Stage III/IV cHL ∨Select
Lymphoma
Type
Previously untreated Stage III/IV cHLPediatric previously untreated high-risk cHLcHL post-auto-HSCT consolidationRelapsed cHLR/R LBCL after ≥2 prior lines of systemic therapyPreviously untreated sALCL or other CD30-expressing PTCLRelapsed pcALCL or CD30-expressing MFRelapsed sALCLLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EfficacySafetyDosageVideo LibraryMOA & Resources ∨MOA &
Resources
Patient ManagementMOA and CD30 TestingResourcesPatient Assistance
Prescribing InformationPatient InformationIndicationsLoadingPatient Site
SafetyMost Common Adverse EventsADCETRIS+AVD has a well-established safety profileAdverse reactions reported in ≥10% of ECHELON-1 patients treated with A+AVD at primary analysis1Derived from laboratory values and adverse reaction data; data are included for clinical reference irrespective of rate between arms.Grouped term includes rash maculopapular, rash macular, rash, rash papular, rash generalized, and rash vesicular.Events were graded using the NCI CTCAE Version 4.03.
Events listed are those having a ≥5% difference in rate between treatment arms.
SARs, Discontinuations, DeathsSerious adverse reactions, dose discontinuations, and on-study deathsFebrile neutropenia and pyrexia were the most common serious adverse reactions in both arms1,2Neutropenia was the most common reason for dose delay in both arms1,2Rates of dose discontinuation1,2On-Study Deaths‡1,2
  • A+AVD: 9 on-study deaths (7 due to neutropenia; none of these patients had received G-CSF prior to developing neutropenia)§
  • ABVD: 13 on-study deaths (11 due to pulmonary-related toxicity)||
Please refer to dose modifications for peripheral neuropathy
Loading
Deaths that occurred within 30 days of last study dose.22 deaths were due to myocardial infarction.21 death was due to cardiopulmonary failure. Cause of other death unknown.2
Peripheral Neuropathy (PN) Resolution Rates
Peripheral neuropathy was identifiable, manageable, and resolved in most cases1,3-7The 3-, 4-, and 5-year data provided are not contained in the approved product labeling.
Data are provided as supportive clinical information.
PN after 2-year median follow-up1,4
  • 67% (442/662) experienced PN1
    • Grade 1 or 2: 56% (372/662)
    • ≥Grade 3: 11% (70/662)
  • Median time to onset (range)1
    • Any grade: 2 months (0-7)
    • Grade 2: 3 months (0-6)
    • Grade 3: 4 months (<1-7)
  • 7% (44/662) discontinued due to PN1,4
PN after 6-year median follow-up1
  • Median time to partial improvement (range)1
    • 2.9 months (<1-50)
  • Median time to complete improvement (range)1
    • <6.6 months (<1-67)
PN is recorded as last observation carried forward. Go to PN data in adolescents and young adultsLoadingAddress PN as early as possible with dose modifications

Recommended dose: 1.2 mg/kg up to a maximum of 120 mg# in combination with AVD every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity1

Scroll left to view table
Severity**Dose modification for PN
Grade 2
  • Reduce dose to 0.9 mg/kg up to a maximum of 90 mg** every 2 weeks
Grade 3
  • Hold ADCETRIS dosing until improvement to Grade 2 or lower
  • Restart at 0.9 mg/kg up to a maximum of 90 mg** every 2 weeks
  • Consider modifying dose of other neurotoxic chemotherapy agents
Grade 4
  • Discontinue dosing

Please see all additional dosing modifications

Patients who develop PN may be able to receive 6 full cycles of treatment with dose modifications1

The dose for patients weighing >100 kg should be calculated based on a weight of 100 kg.1NCI CTCAE Version 4.03 was used in the ECHELON-1 trial, and Version 6.0, current at time of publication (January 2026), is shown here for reference8:
  • Grade 1 sensory PN: Mild symptoms
  • Grade 1 motor PN: Mild symptoms; clinical or diagnostic observations only
  • Grade 2 sensory and motor PN: Moderate symptoms; limiting instrumental ADL
  • Grade 3 sensory and motor PN: Severe symptoms; limiting self-care ADL
  • Grade 4 sensory and motor PN: Life-threatening consequences; urgent intervention indicated
ADL = activities of daily living.
Hand icon with raised palm and radiating lines Identify Symptoms
  • Early identification and patient education of PN signs and symptoms is important. PN may be cumulative1
  • Proactively monitor for signs and symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness at every appointment1
Overlapping speech bubble icons with a plus symbol inside Communicate Early
  • Ask patients to inform their healthcare team as soon as they experience symptoms of PN
  • PN was manageable and resolved for the majority of patients who experienced it with A+AVD1,3
Infusion icon Act With Dose Modifications
  • Through appropriate dose reduction and/or holding, some patients who develop PN may still receive all 6 cycles of ADCETRIS1
Early detection and intervention of PN is critical if PN is present
Explore Patient Management StrategiesLoadingMaking First the Chance Count: Patient Case of a Middle-Aged Adult“I find that PN generally resolves over time.”

Dr Andrew Ip, hematologist-oncologist

Play VideoLoading

Dr Andrew Ip is presenting this program on behalf of Pfizer and is contracted with Pfizer for this service.

G-CSF Primary ProphylaxisStarting G-CSF primary prophylaxis beginning with Cycle 1 of A+AVD may reduce risk of neutropenia1,2,4
  • After 75% of patients had started treatment, G-CSF primary prophylaxis was recommended with A+AVD, as observed rates of neutropenia and febrile neutropenia were higher than anticipated1
Start primary prophylaxis with G-CSF beginning with Cycle 1.1View monitoring and dose modifications for neutropenia1
  • Fatal and serious cases of febrile neutropenia have been reported with ADCETRIS. Prolonged (>1 week) severe neutropenia and Grade 3 or 4 thrombocytopenia or anemia can occur with ADCETRIS
  • Monitor complete blood counts prior to each dose of ADCETRIS
  • Monitor more frequently for patients with Grade 3 or 4 neutropenia
  • Monitor patients for fever
  • Neutropenia led to dose delays of ≥1 drug in 21% of patients; febrile neutropenia led to dose delays in 8% of patients
Scroll left to view table
SeverityDose modifications
Grade 3 or 4Administer G-CSF prophylaxis for subsequent cycles for patients not receiving G-CSF primary prophylaxis
Please refer to recommended dosing information
Secondary MalignanciesSecondary malignancies among patients treated with A+AVD and ABVDThis exploratory 6-year analysis was not specified in the protocol, is descriptive in nature, and offers supportive, but not conclusive, results about secondary malignancies reported in ECHELON-1 participants. This analysis was not powered to determine differences between treatment arms. There was 1 unknown secondary malignancy in the ABVD arm.3Start primary prophylaxis with G-CSF beginning with Cycle 1.1 Go to secondary malignancies data in adolescents and young adultsLoading Please refer to recommended dosing informationLoadingAdditional DataPregnancies among patients treated with A+AVD and ABVD, or their partners#1This exploratory 6-year analysis was not specified in the protocol, is descriptive in nature, and offers supportive, but not conclusive, results about pregnancies reported by ECHELON-1 participants or their partners. This analysis was not powered to determine differences between treatment arms. Fertility was not formally assessed.1Individual female patients or partners of male patients may have recorded multiple pregnancies and multiple pregnancy outcomes.Live births among patients treated with A+AVD and ABVD, or their partners**This exploratory 6-year analysis was not specified in the protocol, is descriptive in nature, and offers supportive, but not conclusive, results about pregnancies reported by ECHELON-1 participants or their partners. This analysis was not powered to determine differences between treatment arms. Fertility was not formally assessed.1Multiple patients or partners of male patients recorded more than 1 live birth.3
  • Per the ECHELON-1 study protocol, female patients who were both lactating and breastfeeding or who had a positive serum pregnancy test during the screening period or a positive pregnancy test on Day 1 before the first dose of study drug were excluded from the study9
  • In summary, female patients were advised to avoid pregnancy, and male patients were advised to use effective methods of contraception.9 It is unknown how many study participants intended to or tried to have children. It is also unknown whether all pregnancies/births were reported9
  • ADCETRIS can cause fetal harm based on findings from animal studies and the drug’s mechanism of action1
  • Verify the pregnancy status of females of reproductive potential prior to initiating ADCETRIS therapy1
  • Advise females of reproductive potential of this potential risk, and to use effective contraception during ADCETRIS treatment and for 2 months after the last dose of ADCETRIS1
  • Advise females to immediately report pregnancy1
  • ADCETRIS may damage spermatozoa and testicular tissue, resulting in possible genetic abnormalities1
  • Advise male patients with female sexual partners of reproductive potential to use effective contraception during ADCETRIS treatment and for 4 months after the last dose of ADCETRIS1
Go to pregnancy data in adolescents and young adultsLoadingAYA Subgroup AnalysisPN incidence and resolution (AYA population)††10PN is recorded as last observation carried forward. Please refer to recommended dosing informationLoadingAdditional safety data for AYA patients after a median follow-up of 6 yearsThis exploratory 6-year analysis was not specified in the protocol, is descriptive in nature, and offers supportive, but not conclusive, clinical information only. This analysis was not powered to determine differences between treatment arms.Female patients or partners of male patients reported pregnancies after a median follow-up of 6 years‡‡3,10This exploratory 6-year analysis was not specified in the protocol, is descriptive in nature, and offers supportive, but not conclusive, results about pregnancies reported by ECHELON-1 participants or their partners. This analysis was not powered to determine differences between treatment arms.Multiple patients or partners of male patients recorded more than 1 live birth.3
  • Fertility was not formally assessed1
  • Per the ECHELON-1 study protocol, female patients who were both lactating and breastfeeding or who had a positive serum pregnancy test during the screening period or a positive pregnancy test on Day 1 before the first dose of study drug were excluded from the study9
  • In summary, female patients were advised to avoid pregnancy, and male patients were advised to use effective methods of contraception.9 It is unknown how many study participants intended to or tried to have children. It is also unknown whether all pregnancies/births were reported9
  • ADCETRIS can cause fetal harm based on findings from animal studies and the drug’s mechanism of action1
  • Verify the pregnancy status of females of reproductive potential prior to initiating ADCETRIS therapy1
  • Advise females of reproductive potential of this potential risk, and to use effective contraception during ADCETRIS treatment and for 2 months after the last dose of ADCETRIS1
  • Advise females to immediately report pregnancy1
  • ADCETRIS may damage spermatozoa and testicular tissue, resulting in possible genetic abnormalities1
  • Advise male patients with female sexual partners of reproductive potential to use effective contraception during ADCETRIS treatment and for 4 months after the last dose of ADCETRIS1​​​​​​​
A+AVEPC: Approved for pediatric patients 2 years and older Explore Pediatric Efficacy Loading < Back Efficacy Loading
Up next >
Dosage Loading
A+AVD = ADCETRIS + doxorubicin, vinblastine, dacarbazine; A+AVEPC = ADCETRIS + doxorubicin, vincristine, etoposide, prednisone, cyclophosphamide; ABVD = doxorubicin, bleomycin, vinblastine, dacarbazine; AVD = doxorubicin, vinblastine, and dacarbazine; AYA = adults and young adolescents; CTCAE = common terminology criteria for adverse events; G-CSF = granulocyte colony–stimulating factor; G-PP = G-CSF primary prophylaxis; ITT = intent-to-treat; NCI = National Cancer Institute; SAR = serious adverse reaction.References:ADCETRIS Prescribing Information. Bothell, WA: Seagen Inc.Data on file. Pfizer Inc.Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in Stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2022;387:310-320.Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378:331-344.Straus DJ, Długosz-Danecka M, Connors JM, et al. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8:e410-e421.Bartlett NL, Straus DJ, Długosz-Danecka M, et al. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma (cHL): 4-year update of the ECHELON-1 study. Poster presented at: 61st Annual Meeting of the American Society of Hematology; December 7-10, 2019; Orlando, FL.Straus D, Collins G, Walewski J, et al. Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leuk Lymphoma. 2020;61:2931-2938.National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). v6.0. Accessed January 31, 2026. https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v6.pdfConnors JM, Jurczak W, Straus DJ, et al. Protocol for: Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2018;378:331-344.Crosswell HE, LaCasce AS, Bartlett NL, et al. Brentuximab vedotin with chemotherapy in adolescents and young adults with stage III or IV classical Hodgkin lymphoma in ECHELON-1. Haematologica. 2024;109(3):982-987.
Available on this page:

Share this patient guide to learn more about managing symptoms associated with PN

Download Guide Loading

To report an adverse event, please call 1‑800‑438‑1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-A1T-USA-1084
You are now leaving PfizerProYou are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.
PP-MCL-USA-0367
Indications

ADCETRIS® (brentuximab vedotin) is indicated for the treatment of:

Previously untreated Stage III/IV cHL

  • Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.

Previously untreated high risk cHL

  • Pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.

cHL post-auto-HSCT consolidation

  • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.

Relapsed cHL

  • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.

Previously untreated sALCL or other CD30-expressing PTCL

  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.

Relapsed sALCL

  • Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.

Relapsed pcALCL or CD30-expressing MF

  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.

Relapsed and Refractory Large B-Cell Lymphoma (LBCL)

  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto‑HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product.

Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.

Important Safety Information

BOXED WARNING

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML): JC virus infection resulting in PML and death can occur in ADCETRIS-treated patients.

CONTRAINDICATION

Contraindicated with concomitant bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation).

WARNINGS AND PRECAUTIONS
Peripheral neuropathy (PN):
ADCETRIS causes PN that is predominantly sensory. Cases of motor PN have also been reported. ADCETRIS-induced PN is cumulative. Monitor for symptoms such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. Patients experiencing new or worsening PN may require a delay, change in dose, or discontinuation of ADCETRIS.

Anaphylaxis and infusion reactions: Infusion-related reactions (IRR), including anaphylaxis, have occurred with ADCETRIS. Monitor patients during infusion. If an IRR occurs, interrupt the infusion and institute appropriate medical management. If anaphylaxis occurs, immediately and permanently discontinue the infusion and administer appropriate medical therapy. Premedicate patients with a prior IRR before subsequent infusions. Premedication may include acetaminophen, an antihistamine, and a corticosteroid.

Hematologic toxicities: Fatal and serious cases of febrile neutropenia have been reported with ADCETRIS. Prolonged (≥1  week) severe neutropenia and Grade 3 or 4 thrombocytopenia or anemia can occur with ADCETRIS.

Administer G-CSF primary prophylaxis beginning with Cycle 1 for adult  patients who receive ADCETRIS in combination with chemotherapy for previously untreated Stage III/IV cHL or previously untreated PTCL or relapsed or refractory LBCL and pediatric patients who receive ADCETRIS in combination with chemotherapy for previously untreated high risk cHL.

Monitor complete blood counts prior to each ADCETRIS dose. Monitor more frequently for patients with Grade 3 or 4 neutropenia. Monitor patients for fever. If Grade 3 or 4 neutropenia develops, consider dose delays,  reductions, discontinuation, or G-CSF prophylaxis with subsequent doses.

Serious infections and opportunistic infections: Infections such as pneumonia, bacteremia, and sepsis or septic shock (including  fatal outcomes) have been reported in ADCETRIS-treated patients. Closely monitor patients during treatment for infections.

Tumor lysis syndrome: Patients with rapidly proliferating tumor and high tumor burden may be at increased risk. Monitor closely and take appropriate measures.

Increased toxicity in the presence of severe renal impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with severe renal impairment. Avoid use in patients with severe renal impairment.

Increased toxicity in the presence of moderate or severe hepatic impairment: The frequency of ≥Grade 3 adverse reactions and deaths was greater in patients with moderate or severe hepatic impairment. Avoid use in patients with moderate or severe hepatic impairment.

Hepatotoxicity: Fatal and serious cases have occurred in ADCETRIS-treated patients. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and occurred after the first ADCETRIS dose or rechallenge. Preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. Monitor liver enzymes and bilirubin. Patients with new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of ADCETRIS.

PML: Fatal cases of JC virus infection resulting in PML have been reported in ADCETRIS-treated patients. First onset of symptoms occurred at various times from initiation of ADCETRIS, with some cases occurring within 3 months of initial exposure. In addition to ADCETRIS therapy, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression. Consider PML diagnosis in patients with new-onset signs and symptoms of central nervous system abnormalities. Hold ADCETRIS if PML is suspected and discontinue ADCETRIS if PML is confirmed.

Pulmonary toxicity: Fatal and serious events of noninfectious pulmonary toxicity, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome, have been reported. Monitor patients for signs and symptoms, including cough and  dyspnea. In the event of new or worsening pulmonary symptoms, hold ADCETRIS dosing during evaluation and until symptomatic improvement.

Serious dermatologic reactions: Fatal and serious cases of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported with ADCETRIS. If SJS or TEN occurs, discontinue ADCETRIS and administer appropriate medical therapy.

Gastrointestinal (GI) complications: Fatal and serious cases of acute pancreatitis have been reported. Other fatal and serious GI complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. Lymphoma with preexisting GI involvement may increase the risk of perforation. In the event of new or worsening GI symptoms, including severe abdominal pain, perform a prompt diagnostic evaluation and treat appropriately.

Hyperglycemia: Serious cases, such as new-onset hyperglycemia, exacerbation of preexisting diabetes mellitus, and ketoacidosis (including fatal outcomes) have been reported with ADCETRIS. Hyperglycemia occurred more frequently in patients with high body mass index or diabetes. Monitor serum glucose and if hyperglycemia develops, administer anti-hyperglycemic medications as clinically indicated.

Embryo-fetal toxicity: Based on the mechanism of action and animal studies, ADCETRIS can cause fetal harm. Advise females of reproductive potential of this potential risk, and to use effective contraception during ADCETRIS treatment and for 2 months after the last dose of ADCETRIS. Advise male patients with female partners of reproductive potential to use effective contraception during ADCETRIS  treatment and for 4 months after the last dose of ADCETRIS.

ADVERSE REACTIONS
The most common adverse reactions (≥20%) in adult patients are  peripheral neuropathy, nausea, fatigue, musculoskeletal pain, constipation, diarrhea, vomiting, pyrexia, upper respiratory tract infection, mucositis, abdominal pain, and rash. The most common laboratory abnormalities (≥20%) in adult patients are decreased  neutrophils, increased creatinine, decreased hemoglobin, decreased lymphocytes, increased glucose, increased ALT, and increased AST. 

The most common Grade ≥3 adverse reactions (≥5%) in combination with AVEPC in pediatric patients were neutropenia, anemia, thrombocytopenia, febrile neutropenia, stomatitis, and infection.

DRUG INTERACTIONS
Concomitant use of strong CYP3A4 inhibitors has the potential to affect  the exposure to monomethyl auristatin E (MMAE). Closely monitor adverse reactions.

USE IN SPECIAL POPULATIONS
Lactation: Breastfeeding is not recommended during ADCETRIS treatment.

Please see full Prescribing Information, including BOXED WARNING, for ADCETRIS.IndicationsADCETRIS® (brentuximab vedotin) is indicated for the treatment of:

Previously untreated Stage III/IV cHL
  • Adult patients with previously untreated Stage III/IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
Previously untreated high risk cHL
  • Pediatric patients 2 years and older with previously untreated high risk cHL, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
cHL post-auto-HSCT consolidation
  • Adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
Relapsed cHL
  • Adult patients with cHL after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.
Previously untreated sALCL or other CD30-expressing PTCL
  • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone.
Relapsed sALCL
  • Adult patients with sALCL after failure of at least one prior multi-agent chemotherapy regimen.
Relapsed pcALCL or CD30-expressing MF
  • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
Relapsed and Refractory Large B-Cell Lymphoma (LBCL)
  • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto‑HSCT or chimeric antigen receptor (CAR) T-cell therapy, in combination with lenalidomide and a rituximab product.